- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04627831
Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
Randomized Parallel Group Study Comparing the Renal Safety of CAPTISOL-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in Patients With Impaired Renal Function Undergoing Coronary Angiography
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged ≥18 years
Referred for a coronary angiography (with or without percutaneous coronary intervention) and must meet either 1 of the following criteria:
- Estimated glomerular filtration rate (eGFR) <45 and ≥15 mL/min/1.73 m2 as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation; or
eGFR <60 and ≥45 mL/min/1.73 m2 as determined by the CKD-EPI equation and at least 1 of the following conditions:
- Age >75 years
- Diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤10%
- New York Heart Association (NYHA) class II or III heart failure
- Albuminuria with urine albumin-to-creatinine ratio (UACR) or urine protein-to- creatinine ratio (UPCR) ≥300 and ≤4000 mg/g; or
- Anemia, with hemoglobin levels ≥8 g/dL but <12.0 g/dL in women and <13.0 g/dL in men, as defined by the World Health Organization
If female, must also meet any 1 of the following criteria:
- Surgically sterile with bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy
- Postmenopausal with amenorrhea for at least 1 year and follicle-stimulating hormone in the postmenopausal range; or
- Is a woman of childbearing potential, non-pregnant and non-lactating at Screening, and must agree to use a protocol-recommended method of birth control or abstain from heterosexual intercourse, beginning at least 30 days prior to and until 30 days following investigational contrast agent administration
If a male who can father a child, must also meet all of the following criteria:
- Willing to use a protocol-recommended method of birth control, ie, a double barrier approach (eg, condoms with spermicide) or abstain from heterosexual intercourse with women of childbearing potential, from Day 1 until at least 90 days after investigational contrast agent administration; and
- Willing to refrain from sperm donation from Day 1 until at least 90 days after investigational contrast agent administration
- Willing to undergo protocol-recommended blood and urine collections, physical examinations, and laboratory investigations; and
- Willing and able to provide written informed consent
Exclusion criteria
- eGFR <15 mL/min/1.73 m2
- Reduction in eGFR by approximately 25% that is considered to be acute per the Investigator's judgment
- Body weight >125 kg
Uncorrected clinically significant abnormalities of clinical laboratory assessments which, in the Investigator's opinion, will interfere with the study conduct, including but not limited to the following:
- HbA1c >10%
- Blood glucose >270 mg/dL
- Hemoglobin <8 g/dL
- Albuminuria with UACR or UPCR >4000 mg/g; or
- Aspartate aminotransferase or alanine aminotransferase >3 x upper limit of reference range
- Positive test for severe acute respiratory syndrome coronavirus 2 RNA at Screening;
- Positive test for human immunodeficiency virus antibody, hepatitis B surface antigen, or hepatitis C virus RNA at Screening
- Uncontrolled hypertension, with systolic blood pressure (BP) >180 mmHg or diastolic BP >110 mmHg at Screening, based on the average of 3 BP measurements obtained from the patient's dominant arm
- Hypotension, that is considered to be of recent occurrence per the Investigator's judgment, and required resuscitation with intravenous fluids
- Non-cardiac acute illness or injuries that, in the opinion of the Investigator, could put the patient at risk or obscure the interpretation of the results of the study
- Known allergy or sensitivity to iodinated contrast agents, Captisol, or any of the excipients in the study contrast agent that cannot be adequately managed with prophylactic treatment per the Investigator's judgment and Good Clinical Practice
- Known allergy to heparin, history of heparin-induced thrombocytopenia, or history of heparin induced thrombocytopenia with thrombosis
Chronic disease(s) that, in the opinion of the Investigator, could interfere with (or for which the treatment might interfere with) the conduct of the study or interpretation of the study results or would place the patient at undue risk by participating in the study, including but not limited to the following:
- NYHA class IV or decompensated heart failure; or
- Cirrhosis of the liver
- Inability to receive periprocedural intravenous volume expansion
- Received contrast media within 10 days prior to the scheduled coronary angiography
- Unable or not willing to come off non-steroidal anti-inflammatory drugs, including ibuprofen, for at least 24 hours before the scheduled procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CE-Iohexol
Subject is randomized to receive CE-Iohexol Injection
|
Captisol-Enabled™ Iohexol as needed for the diagnostic procedure.
Volume will be determined according to medical need.
Other Names:
|
Active Comparator: Omnipaque™ (Iohexol)
Subject is randomized to receive Omnipaque™ Iohexol Injection
|
Iohexol as needed for the diagnostic procedure.
Volume will be determined according to medical need.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of contrast-induced acute kidney injury (CI-AKI)
Time Frame: 7 days
|
Evaluate the incidence of CI-AKI in patients with impaired renal function undergoing coronary angiography, from baseline to any blood draw within 7 days following intravascular administration of CE-iohexol compared with Omnipaque (iohexol).
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Image quality
Time Frame: Day 1
|
Compare image quality of coronary angiography in patients administered CE-iohexol versus iohexol.
|
Day 1
|
Change in serum creatinine (SCr)
Time Frame: 7 days
|
Evaluate the changes in SCr in patients administered CE-iohexol versus iohexol.
|
7 days
|
Proportion of patients exhibiting an increase in SCr
Time Frame: 7 days
|
Evaluate the proportion of patients exhibiting an increase in SCr following intravascular administration of CE-iohexol compared with iohexol.
|
7 days
|
Change in serum cystatin C
Time Frame: 7 days
|
Evaluate the changes in serum cystatin C in patients administered CE-iohexol versus iohexol.
|
7 days
|
Incidence of Adverse Events
Time Frame: 30 days
|
The number of patients with adverse events (AE) and serious adverse events will be assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.0.
Monitoring for Major Adverse Cardiac and Renal Events (MARCEs) will be part of the AE assessment.
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in novel biomarkers of renal injury
Time Frame: 7 days
|
Evaluate the change in blood and urine biomarkers of renal injury from baseline to peak at 48 hours in patients administered CE-iohexol versus iohexol.
Biomarkers may include neutrophil gelatinase-associated lipocalin, liver-type fatty acid binding protein and kidney injury molecule-1.
|
7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Keith Marschke, PhD, Ligand Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CE-Iohexol - Study 201
- Ligand 201 (Other Identifier: Ligand Pharmaceuticals)
- CAP201 (Other Identifier: Ligand Pharmaceuticals)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contrast-induced Nephropathy
-
Singapore General HospitalActive, not recruitingContrast-induced NephropathySingapore
-
Chinese PLA General HospitalUnknownContrast-induced NephropathyChina
-
Memorial University of NewfoundlandUniversity of AlbertaWithdrawnContrast Induced NephropathyCanada
-
Sun Yat-sen UniversityCompletedContrast Induced NephropathyChina
-
Isfahan University of Medical SciencesUnknownContrast-Induced NephropathyIran, Islamic Republic of
-
Noura gamalNot yet recruitingContrast-induced Nephropathy
-
CardioRenal Systems, Inc.Active, not recruitingContrast Induced NephropathyUnited States
-
rabab ahmed mohamedCairo UniversityCompletedContrast-induced Nephropathy
-
Assiut UniversityUnknownContrast-induced Nephropathy
-
Isfahan University of Medical SciencesCompletedContrast-Induced NephropathyIran, Islamic Republic of
Clinical Trials on CE-Iohexol
-
CyDex Pharmaceuticals, Inc.Syneos Health; Ligand PharmaceuticalsCompletedContrast-induced Nephropathy | Coronary AngiographyCanada
-
UNC Lineberger Comprehensive Cancer CenterRecruiting
-
Genzyme, a Sanofi CompanyTerminatedFabry DiseaseAustria, Brazil, France, United States, Argentina, Belgium, Canada, Finland, Hungary, Norway, Poland, Spain, Taiwan, United Kingdom
-
Nova Scotia Health AuthorityCompletedContrast Media DosingCanada
-
University Hospital, ToursCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University Hospital, GhentUniversity GhentCompletedAcute Kidney Injury | Pharmacokinetics | Renal Function | Augmented Renal Clearance | Iohexol | Critically Ill ChildrenBelgium
-
PfizerCompletedWeight Management | Treatment Of ObesityCanada, United States, Bulgaria, Spain, Mexico, India, Puerto Rico
-
Assistance Publique - Hôpitaux de ParisRecruitingCritically Ill | Augmented Renal ClearanceFrance